Victoza

The injectable Type 2 diabetes drug Victoza works by stimulating insulin production. It belongs to a class of drugs called GLP-1 mimetics. Studies link Victoza to pancreatitis, thyroid cancer and pancreatic cancer.

*Please seek the advice of a medical professional before discontinuing the use of this drug.

Victoza pen

Dosage: Prefilled 6 mg/ML injection pen with dosages of 0.6 mg, 1.2 mg, 1.8 mg daily

Used to Treat: Type 2 diabetes

Interactions: May impact absorption of oral medications

Related Drugs: Januvia, Janumet, Byetta, Nesina, Onglyza

Black Box Warnings: Risk of thyroid C-cell tumors

Active Ingredient: Liraglutide

FDA Approval: 2010

Victoza (liraglutide) is a once-a-day drug manufactured by Novo Nordisk. The Food and Drug Administration (FDA) approved the drug in January 2010. Novo Nordisk also manufactures another drug called Saxenda. Like Victoza, it is also a liraglutide injection. But Saxenda is indicated for weight management and is not indicated for treating Type 2 diabetes. Though it is effective in controlling blood sugar, Victoza may be linked to dangerous side effects, including pancreatitis and thyroid cancer. Victoza is similar to Amylin Pharmaceuticals’ injectable diabetes drug Byetta (exenatide) in that it aims to lower blood sugar by mimicking a hormone called GLP-1. As of March 2013, almost 1 million Americans had taken Victoza, and the drug remains the market leader in GLP-1 mimetics.

Thyroid gland cancerVictoza may be linked to pancreatic cancer

Worldwide Victoza sales for 2012 topped out at $1.7 billion, accounting for more than 12 percent of Novo Nordisk’s full-year sales. By 2016, the company reported U.S. sales of over $2 billion. A month’s supply of Victoza, at the average dose, costs about $500 without insurance; in comparison, Byetta costs about $170 per month.

Celebrity chef Paula Deen was a spokeswoman for Victoza until June 2013, when Novo Nordisk cut ties with her after she admitted to having used racist language. She originally signed a $6 million, two-year contract.

How Does Victoza Work?

Victoza works by stimulating natural insulin production in the pancreas. Along with a healthy diet and exercise routine, the drug effectively reduces blood sugar. Victoza can be used in combination with oral diabetes medications such as Actos, Avandia, Amaryl (glimepiride) and metformin but may impact the absorption of these drugs since it delays gastric emptying.

pancreasVictoza stimulates insulin production in the pancreas

Victoza is not an insulin product. It is 97 percent similar to a bodily hormone called GLP-1 (glucagon-like peptide-1). This hormone affects the liver, pancreas and gut and helps control glucose, insulin and gastric emptying.

When a person eats, the small intestine releases this hormone, which helps the pancreas release the appropriate amount of insulin to help regulate blood sugar. More specifically, GLP-1 activates pancreatic cells called beta cells that make insulin. By mimicking GLP-1, Victoza signals the pancreas to create more insulin.

Insulin and Blood Sugar

Insulin is a hormone made in the pancreas and released into the blood. It plays a significant role in metabolism, or the way the body uses food for energy. After carbohydrates, such as sugars and starches found in many foods we eat, are broken down by the digestive tract into glucose (a form of sugar) it enters the bloodstream, where insulin helps cells in the body absorb it for energy.

Did You Know

The hormone insulin is a main regulator of the glucose (sugar) levels in the blood.

When the amount of glucose in a person’s blood rises after a meal, the pancreas releases insulin into the blood to assist muscle, fat and liver cells to absorb the glucose thereby lowering blood glucose levels in the body. Excess glucose is then stored by liver and muscle tissue, where it becomes glycogen. Insulin also lowers blood glucose levels by reducing the production of glucose in the liver.

When insulin resistance occurs, the body’s cells do not respond properly to the hormone, and they are unable to easily absorb glucose from the bloodstream. This results in the body needing higher levels of insulin to help glucose enter the cells. When special cells in the pancreas called beta cells cannot keep up with the increased demand for insulin, excess glucose builds up in the bloodstream leading to the development of type 2 diabetes.

Medications that work to stimulate the production of the much-needed insulin can help patients with type 2 diabetes to better process blood sugar and prevent long-term complications of the disease.

Victoza Dosage Recommendations

Patients take Victoza once a day by inserting the prescription pen into their thigh, upper arm or stomach. Doctors instruct patients on how to use the Victoza pen. The prefilled 6 mg/mL pens can last up to 30 days or more, depending on the daily dosage (0.6 mg, 1.2 mg or 1.8 mg.)

If patients are taking Victoza with insulin, they should inject each drug separately and never mix the two solutions.

How Effective is Victoza?

During one 52-week clinical trial, 6,090 patients who received Victoza once a day as a stand-alone treatment saw a 1.1 percent decrease in A1C (which measures the average glucose concentration over a two- to three-month period) when taking 1.8 mg of the drug; patients taking 1.2 mg averaged a 0.8 percent decrease. For people with Type 2 diabetes, an A1C level of 7 percent or less is ideal, though some doctors may allow a level of 8 percent. Even a 1 percent drop can make a difference for people trying to control their blood sugar.

While weight loss is not a primary goal for people taking Victoza, it may be a benefit for controlling blood sugar. Patients lost an average 5.5 pounds with a 1.8 mg dosage; for patients taking a 1.2 mg dosage, the average weight loss was 4.6 pounds.

Victoza also helped lower fasting blood glucose in people with Type 2 diabetes. A normal fasting blood glucose (fasting blood sugar level) is between 70 mg and 100 mg. In people with Type 2 diabetes, these levels are much higher. Controlling blood glucose can help prevent complications of diabetes such as cardiovascular disease. Another 52-week trial found that patients experienced about a 20 percent reduction in FPG (fasting glucose level) when taking 1.8 mg of Victoza daily, while blood-glucose levels in patients taking 1.2 mg dropped about 16 percent. The FPG levels began to decline within two weeks.

Victoza reduced the risk of heart attack, stroke and death from cardiovascular issues by about 13 percent in patients with Type 2 diabetes.

In a 2016 study published in the New England Journal of Medicine by Steven P. Marso and colleagues, researchers found that Victoza reduced the risk of heart attack, stroke and death from cardiovascular issues by about 13 percent in patients with Type 2 diabetes.

Common Side Effects of Victoza

In clinical trials for Victoza-related side effects, Novo Nordisk gathered data from 1,673 patients. The average age of trial participants was 58 years, and the majority of participants were white males. Trial participants took Victoza for about 37 weeks. The most common side effects occurred in 5 percent or more of study participants. Side effects increased with the highest dose of the drug.

Common side effects include:

  • Nausea
  • Diarrhea
  • Headache
  • Nasopharyngitis (common cold)
  • Vomiting
  • Decreased appetite
  • Dyspepsia (discomfort in upper abdomen or chest)
  • Upper respiratory tract infection
  • Constipation
  • Back pain
  • Gastrointestinal problems
  • Injection site reactions
  • Hypoglycemia

Serious Side Effects of Victoza

The Institute for Safe Medication Practices (ISMP) reported that the FDA’s clinical safety reviewer originally voted against approving the drug because of its link to thyroid tumors, insufficient study to rule out increased heart attack and stroke risk, as well as an increased risk for pancreatitis. In 2011, the FDA published a warning that doctors weren’t fully aware of thyroid risks associated with Victoza. That notice also mentioned that clinical trials suggested an increased risk of pancreatitis in Victoza patients.

In addition to the common side effects discovered in clinical trials, post-marketing reports revealed more serious adverse events linked to Victoza. Because post-marketing side effect reports are voluntary, Novo Nordisk cannot estimate the frequency of these issues.

Serious side effects reported in post-marketing reports include:

  • Medullary thyroid carcinoma (thyroid cancer)
  • Dehydration
  • Acute kidney failure or worsening of chronic kidney failure requiring dialysis
  • Angioedema (acute swelling of the skin, usually around the eyes, lips and face) and allergic reactions
  • Acute pancreatitis, hemorrhagic and necrotizing pancreatitis that may result in death
  • Liver problems

Black Box Warning for Thyroid Cancer

Victoza black box warning

Novo Nordisk found that Victoza causes tumors of the thyroid gland in rats, including malignant tumors. Since the drug is fairly new and since thyroid cancer is rare in humans, the FDA has stated that it’s difficult to say whether the drug can cause thyroid cancer in humans.

However, Victoza does come with a black-box label that warns of the risk of thyroid C-cell tumors and possible thyroid cancer.

Is Victoza Safe for Me?

Victoza has several contraindications that patients should speak with their doctors about before taking the drug.

The drug’s label and the FDA warn that people with a personal or family history of thyroid cancer or Multiple Endocrine Neoplasia syndrome type 2 should not take Victoza.

Other possible contraindications include:

  • Gallstones
  • High triglyceride levels
  • Severe stomach problems and digestive issues
  • Pregnant or plan to become pregnant
  • Pancreatitis
  • Alcoholism
  • Liver or kidney problems
  • Breastfeeding or plan to breastfeed

Author

Michelle Y. Llamas is a senior content writer. She is also the host of Drugwatch Podcast where she interviews medical experts as well as patients affected by drugs and medical devices. She has written medical and legal content for several years — including an article in The Journal of Palliative Medicine and an academic book review for Nova Science Publishers. With Drugwatch, she has developed relationships with legal and medical professionals as well as with several patients and support groups. Prior to writing for Drugwatch, she spent several years as a legal assistant for a personal injury law firm in Orlando. She obtained her English – Technical Communication degree from the University of Central Florida. She is a committee member with the American Medical Writers Association.


Hide Sources

  1. National Institute of Health. (2017). Victoza-liraglutide injection. Retrieved from https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=5a9ef4ea-c76a-4d34-a604-27c5b505f5a4#i4i_contraindications_id_a5e28663-ffb6-40fb-baa4-2ee770b687ff
  2. Cortez, M. (2016, June 13). Novo Slumps as Study on Victoza's Heart Impact Disappoints. Retrieved from https://www.bloomberg.com/news/articles/2016-06-13/novo-s-victoza-cuts-heart-complications-13-percent-in-diabetics
  3. Novo Nordisk. (2016). Novo Nordisk Annual Report 2016. Retrieved from http://www.novonordisk.com/content/dam/Denmark/HQ/AnnualReport/2016/PDF/Novo-Nordisk-Annual-Report-2016.pdf
  4. CBS News. (2013, March 14). FDA reviewing new diabetes drugs due to pancreatic disease risk. Retrieved from http://www.cbsnews.com/news/fda-reviewing-new-diabetes-drugs-due-to-pancreatic-disease-risk/
  5. U.S. Food and Drug Administration (FDA). (2010, January 25). FDA Approves New Treatment for Type 2 Diabetes [Press release]. Retrieved from http://www.fda.gov/
  6. Edwards, J. (2010, January 23). Cancer Warning on Novo's Victoza Is Sanofi's Chance for Revenge. CBS News. Retrieved from http://www.cbsnews.com/news/cancer-warning-on-novos-victoza-is-sanofis-chance-for-revenge/
  7. Franks, A.S., Geroge, C.M., & Lee, P.H. (2012, November). Pancreatitis: a potential complication of liraglutide? University of Tennessee Health Science Center, College of Pharmacy, Department of Clinical Pharmacy. Retrieved from http://www.ncbi.nlm.nih.gov/pubmed/23136352
  8. Moskin, J. (2012, January 17). Chef Has Diabetes, and Some Say ‘I Told You So’. The New York Times. Retrieved from http://www.nytimes.com/2012/01/18/dining/paula-deen-says-she-has-type-2-diabetes.html
  9. Moskin, J. & Pollack, A. (2013, June 27). Diabetes Drug Maker Suspends Deal With Deen. The New York Times. Retrieved from http://www.nytimes.com/2013/06/28/dining/diabetes-drug-maker-suspends-deal-with-deen.html
  10. Novo Nordisk. (2013, May 1). Financial report for the period 1 January 2013 to 31 March 2013. Retrieved from http://www.novonordisk.com/
  11. Sacks, D. (2011, February). A1C Versus Glucose Testing: A Comparison. Diabetes Care. Retrieved from http://care.diabetesjournals.org/content/34/2/518.full
  12. Staton, T. (2013, July 31). FDA clears Merck's Januvia, sister meds of new pancreatitis worries. FiercePharma. Retrieved from http://www.fiercepharma.com/story/fda-clears-mercks-januvia-sister-meds-new-pancreatitis-worries/2013-07-31
  13. U.S. Judicial Panel on Multidistrict Litigation. Hearing Information. Retrieved from http://www.jpml.uscourts.gov/hearing-information
  14. U.S. Food and Drug Administration (FDA). (2010, January 26). Liraglutide (marketed as Victoza) Information. Retrieved from http://www.fda.gov/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/ucm198437.htm
  15. U.S. Food and Drug Administration (FDA). (2010, January 26). Questions and Answers - Safety Requirements for Victoza (liraglutide). Retrieved from http://www.fda.gov/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/ucm198543.htm
  16. U.S. Food and Drug Administration (FDA). Medication Guide: Victoza (VIC-tow-za) (liraglutide [rDNA origin]) Injection. Retrieved from http://www.fda.gov/downloads/Drugs/DrugSafety/UCM199170.pdf
  17. Victoza. Retrieved from https://www.victozapro.com/
  18. Institute for Safe Medication Practices. (2011, May 19). QuarterWatch: 2010 Quarter 3: New signals for liraglutide, quetiapine and verenicline. Retrieved from http://www.ismp.org/quarterwatch/2010Q3.pdf
  19. Food and Drug Administration. (2011, June 13). Victoza (liraglutide [rDNA origin]) Injection: REMS - Risk of Thyroid C-cell Tumors, Acute Pancreatitis. Retrieved from http://www.fda.gov/
  20. NIDDK. NIH. (2009, August). Prediabetes & Insulin Resistance. Retrieved from: https://www.niddk.nih.gov/health-information/diabetes/overview/what-is-diabetes/prediabetes-insulin-resistance